Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Executive Summary
Former FDA Deputy Commissioner Sharfstein suggests Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.
You may also be interested in...
Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma
Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.
Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest
The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.